Cardiovascular Effects of the Cyclooxygenase Inhibitors
- 1 March 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 49 (3) , 408-418
- https://doi.org/10.1161/01.hyp.0000258106.74139.25
Abstract
No abstract availableThis publication has 82 references indexed in Scilit:
- Celecoxib for the Prevention of Colorectal Adenomatous PolypsNew England Journal of Medicine, 2006
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- Non‐selective nonsteroidal anti‐inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?British Journal of Clinical Pharmacology, 2006
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJournal of Clinical Investigation, 2005
- Prostacyclin protects against elevated blood pressure and cardiac fibrosisCell Metabolism, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes MellitusArchives of internal medicine (1960), 2005
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000